Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 13/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 13/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 12/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND2 | P30279 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311444 | 0.84 | KDM4E (0.40) | KDM4EPDE1APDE1BPDE1CKDM4D | |
| SCHEMBL14016377 | 0.83 | KDM4E (0.50) | KDM4EPDE1APDE1BPDE1CKDM4D | |
| SCHEMBL25612718 | 0.77 | ADORA3 (0.40) | KDM4EPDE1APDE1BPDE1CKDM4D | |
| SCHEMBL21311189 | 0.76 | KDM4E (0.44) | KDM4EPDE1APDE1BPDE1CKDM4D | |
| SCHEMBL24983893 | 0.75 | KDM4E (0.43) | KDM4EPDE1APDE1BPDE1CKDM4D | |
| SCHEMBL3862440 | 0.75 | RECQL (0.42) | KDM4EL3MBTL1 | |
| SCHEMBL31469698 | 0.74 | KMO (0.39) | L3MBTL1CDK4CCND1CCND2CCND3 | |
| SCHEMBL15970721 | 0.73 | HDAC8 (0.46) | — | |
| SCHEMBL983824 | 0.73 | KDM4E (0.50) | KDM4EPDE1APDE1BPDE1CKDM4D | |
| SCHEMBL18926932 | 0.72 | KDM4E (0.46) | KDM4EKDM4DFGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 3520/4885PDE1A 2898/4885PDE1B 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.